Post-Authorisation Safety Study of Lesinurad - SATURATES

Study identifier:D5310R00016

ClinicalTrials.gov identifier:NCT04072471

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

Post-Authorisation Safety Study of Lesinurad

Medical condition

Gout, Hyperuricemia

Phase

N/A

Healthy volunteers

No

Study drug

Zurampic®, Control group: xanthine oxidase inhibitor monotherapy

Sex

All

Actual Enrollment

0

Study type

Observational

Age

18 Years +

Date

Study Start Date: 29 Jan 2021
Estimated Primary Completion Date: 30 Jun 2023
Estimated Study Completion Date: 30 Jun 2023

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Mar 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria